The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

(2016) Anna Baghdasaryan et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease

(2012) A. Zarrinpar et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

(2012) Thuy-Anh Le et al.   HEPATOLOGY

Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study

(2011) M. Simrén et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation

(2011) William D Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism

(2010) Gemma Brufau et al.   HEPATOLOGY

Chronic Diarrhea Due to Excessive Bile Acid Synthesis and Not Defective Ileal Transport: A New Syndrome of Defective Fibroblast Growth Factor 19 Release

(2009) Alan F. Hofmann et al.   Clinical Gastroenterology and Hepatology